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Disorder Working Group of the Psychiatric Genomics Consortium, Bernhard T. Baune,
Gerome Breen, Douglas F. Levinson, Cathryn M. Lewis, Nick G. Martin, Elliot N. Nelson,
Dorret I. Boomsma, Hans J. Grabe, Naomi R. Wray, and Brenda W.J.H. PenninxABSTRACT
BACKGROUND: The heterogeneity of genetic effects on major depressive disorder (MDD) may be partly attributable
to moderation of genetic effects by environment, such as exposure to childhood trauma (CT). Indeed, previous
findings in two independent cohorts showed evidence for interaction between polygenic risk scores (PRSs) and CT,
albeit in opposing directions. This study aims to meta-analyze MDD-PRS 3 CT interaction results across these two
and other cohorts, while applying more accurate PRSs based on a larger discovery sample.
METHODS: Data were combined from 3024 MDD cases and 2741 control subjects from nine cohorts contributing to
the MDD Working Group of the Psychiatric Genomics Consortium. MDD-PRS were based on a discovery sample of
w110,000 independent individuals. CT was assessed as exposure to sexual or physical abuse during childhood. In a
subset of 1957 cases and 2002 control subjects, a more detailed five-domain measure additionally included
emotional abuse, physical neglect, and emotional neglect.
RESULTS: MDD was associated with the MDD-PRS (odds ratio [OR] = 1.24, p = 3.63 1025, R2 = 1.18%) and with CT
(OR = 2.63, p = 3.5 3 10218 and OR = 2.62, p = 1.4 31025 for the two- and five-domain measures, respectively). No
interaction was found between MDD-PRS and the two-domain and five-domain CT measure (OR = 1.00, p = .89 and
OR = 1.05, p = .66).
CONCLUSIONS: No meta-analytic evidence for interaction between MDD-PRS and CT was found. This suggests that
the previously reported interaction effects, although both statistically significant, can best be interpreted as chance
findings. Further research is required, but this study suggests that the genetic heterogeneity of MDD is not
attributable to genome-wide moderation of genetic effects by CT.
Keywords: Childhood trauma, Depression, Genetics, Interaction, Meta-analysis, Polygenic risk
https://doi.org/10.1016/j.biopsych.2017.09.009Recent studies have found the first associated genetic variants
for major depressive disorder (MDD) and depressive com-
plaints (1–3), but research on MDD still has not met the suc-
cess of research on schizophrenia, for which 108 genetic
variants were found in 2014 (4). This discrepancy is attributable
to several factors, including the higher population prevalence
of MDD (so that the difference in liability between cases and
control subjects is smaller than in schizophrenia cases) (5,6),
the lower heritability of MDD (assuming the same degree of
polygenicity in terms of number of risk loci) (5), and the greater
genetic and phenotypic heterogeneity of MDD (7). To illustrateSEE COMMENTAR
ª 2017 Society of Biological Psychiatry.
ical Psychiatry July 15, 2018; 84:138–147 www.sobp.org/journalthe possible consequence of heterogeneity, Wray and Maier (8)
showed that the power to detect a causal single nucleotide
polymorphism (SNP) decreases dramatically when a disorder
is caused by two distinct pathways, while Milaneschi et al.
(9,10) found that genetic effects in those with typical MDD
might partially differ from genetic effects in those with atypical
MDD.
Another source of genetic heterogeneity may arise from
gene-by-environment (G 3 E) interaction: the moderation of
genetic effects on MDD by specific environmental factors.
Much research concerning G 3 E interaction has beenY ON PAGE 82
ISSN: 0006-3223
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Psychiatryconducted with candidate genes, in particular the interaction
between the serotonin transporter gene 5-HTTLPR and child-
hood trauma (CT) (11), but this research has produced con-
tradictory findings (12–15) that have been attributed, at least in
part, to publication bias (16). Recently, Culverhouse et al.
published results from a collaborative meta-analysis showing
no evidence for interaction between 5-HTTLPR and CT (17)
based on a previously published protocol for analyses (18).
Nevertheless, in the last couple of years, methods have been
developed to assess the combined impact of all genotyped
SNPs, such as polygenic risk score (PRS) analyses (19). Ken-
dler (20) proposed that a confirmed main effect is a desirable
condition for G 3 E interaction testing. This suggests that
PRSs may be preferable over candidate genes to test for G3 E
interaction, because PRSs have a confirmed significant effect
on MDD (21,22) contrasting the nonreplicated and non-
consistent effects of candidate genes (23,24).
In G 3 E interaction research, numerous environmental
factors can be tested, which may have catalyzed publication
bias in the candidate gene literature (16) and may also present
as a challenge for G 3 E interaction tests with PRSs. Never-
theless, a plausible environmental factor to test in the context
of G 3 E interaction is CT, which is one of the strongest risk
factors with a lifelong impact on MDD risk (25) and may
perhaps be more uniformly defined than stress later in life.
Moreover, exposure to CT has been hypothesized to distin-
guish a clinically and neurobiologically distinct subtype of
MDD, because MDD patients exposed to CT have an earlier
onset, more chronic course, higher severity with more neuro-
vegetative and psychotic symptoms, more comorbidities,
more suicide attempts, and poorer treatment outcome than
MDD patients that did not experience CT (26).
Following this reasoning, Peyrot et al. (27) tested for G 3 E
interaction between PRS and CT in the NESDA (Netherlands
Study of Depression and Anxiety) and found a significantly
stronger impact ofPRSonMDDrisk in individuals exposed toCT
compared with that on individuals not exposed to CT. In a
replication study, Mullins et al. (28) found a significant but
opposing interaction effect in the RADIANT-UK sample with a
stronger impact of PRS on MDD risk in those unexposed to CT.
These opposing findings, both of which were significant, are not
well understood, and it remains unclear whether these reflect
actual differences between cultures, differences between
recruitment of participants into cohorts, or chance findings. The
aim of the current study is 1) to reanalyze NESDA andRADIANT-
UK with more accurate PRSs based on discovery results from
w110,000 individuals (compared with w15,000 applied previ-
ously) and 2) to place the NESDA and RADIANT-UK findings in a
broader perspective by meta-analyzing their results with seven
additional cohorts from the Psychiatric Genomics Consortium
(PGC) MDD wave 2 (29). Secondary analyses used PRS calcu-
lated from discovery genome-wide association study (GWAS)
results for schizophrenia and bipolar disorder, as these are
genetically related to MDD (7,30).
METHODS AND MATERIALS
Subjects
Subjects were recruited from the PGC wave 2, which com-
bines genotype and phenotype data of individuals ofBiologicalEuropean ancestry in 29 different cohorts (29). The combined
samples include data of 16,823 MDD cases and 25,632
control subjects. Of these 29 cohorts, nine cohorts included a
measure of CT: Cognition and Function in Mood Disorders
Study (COFAMS) from Australia (31); Depression Gene
Network (DGN) from the U.S. (32); the NESDA (33); the
Queensland Institute of Medical Research (QIMR in three
different cohorts defined by genotyping platform) from
Australia (23); RADIANT-UK (34); and SHIP (Study of Health in
Pomerania) (both SHIP-0 and SHIP-TREND) from Germany
(see Supplemental Table S1 for more detailed information)
(35). Briefly, SHIP-O, SHIP-T, and QIMR are community
studies with MDD cases and screened control subjects
defined from responses to self-report questionnaires, while
the other studies recruit MDD cases from inpatient or
outpatient clinics and recruit screened control subjects, with
both cases and control subjects completing the same CT
questionnaires. The definition of MDD in all studies was
based on structured psychiatric interviews following DSM-IV
criteria.
Childhood Trauma Questionnaire
The Childhood Trauma Questionnaire (CTQ) was applied to
assess CT, defined as trauma before the age of 16, in five of
the nine cohorts (COFAMS, NESDA/Netherlands Twin Reg-
ister (NTR), RADIANT-UK, SHIP-0, and SHIP-TREND). The
CTQ covers the five domains of sexual abuse, physical
abuse, emotional abuse, emotional neglect, and physical
neglect. Each domain is assessed by five questions (scored 1
to 5) resulting in a domain score ranging from 5 to 25, and an
overall CTQ continuous score ranging from 25 to 125 (36).
Per domain, cutoffs were applied to define a narrow definition
of CT separating no or mild trauma from moderate or severe
trauma (Supplemental Methods). From this, an overall
dichotomous CTQ indicator was constructed to separate
trauma in any of the five domains (indicator = 1) from trauma
in none of the domains (indicator = 0). The analyses were
based on the continuous and dichotomous five-domain CT
scores. The five domains were highly correlated: all pairwise
correlation coefficients were larger than 0.4 except for sexual
abuse, which was slightly less connected (Supplemental
Table S2), as has previously also been reported by Spin-
hoven et al. (37).
Other CT Instruments
In addition to the five cohorts that assessed CT with the CTQ
instrument, four additional PGC cohorts (DGN and the three
subcohorts of QIMR) assessed CT with other instruments
(before the age of 18 in QIMR). To obtain the largest possible
dataset, CT information was matched across all nine cohorts
for sexual abuse and physical abuse (Supplemental
Methods). A broad definition (no abuse vs. mild, moderate,
or severe abuse) was applied to create a CT indicator
separating those with trauma (exposed to sexual and/or
physical abuse) from those not exposed to CT (neither
exposed to sexual nor physical abuse). The correlation
(Spearman’s rho) between the two-domain dichotomous CT
indicator and the five-domain continuous CT score equaled
.50 (p , 2 3 10216).Psychiatry July 15, 2018; 84:138–147 www.sobp.org/journal 139
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The cohorts were genotyped following their local protocols,
after which quality control and imputation against the reference
panel of the 1000 Genomes Project (38) were performed
centrally in the PGC per cohort (29). The SNP probabilities
were converted to best-guess data with a genotype call
probability cutoff of 0.8, after which individuals were removed
with a missing rate .2%. A total of 1,171,526 HapMap 3 SNPs
passed postimputation quality control in at least two of nine
batches (missing rate ,2%, minor allele frequency .0.01, and
imputation INFO score .0.6). These 1,171,526 SNPs were
used to calculate the genetic relatedness matrix (GRM) with
PLINK 2.0 (39), which was thus based on a different set of
SNPs for individuals from each cohort and between each pair
of cohorts (Supplemental Table S3), in this way providing
genome-wide coverage of well-described HapMap 3 SNPs.
From the GRM, unrelated individuals were selected with
relatedness ,0.05, and ancestry informative principal com-
ponents were calculated with GCTA (40).
Polygenic Risk Scores
PRSs for MDD (MDD-PRS) were based on meta-analysis of the
GWAS results from the 20 PGC MDD wave 2 cohorts with no
CT information available (10,409 cases, 18,640 control sub-
jects) (29), deCODE (1980 cases, 9536 control subjects) (29),
Generation Scotland (997 cases, 6358 control subjects)
(41,42), GERA (Genetic Epidemiology Research on Adult
Health and Aging) (7162 cases, 38,307 control subjects) (43),
The Lundbeck Foundation Initiative for Integrative Psychiatric
Research (iPsych) (16,242 cases, 15,847 control subjects) (29),
and UK Biobank (8248 cases, 16,089 control subjects) (44,45).
This discovery sample comprised 45,038 cases and 104,777
control subjects yielding a power similar to a sample of 56,134
cases and 56,134 control subjects (neffective = 56,134 1
56,134 = 112,268). Additional PRSs were based on GWAS
results from schizophrenia (SCZ-PRS) (4) and bipolar disorder
(BIP-PRS) (46), because these disorders are genetically related
to MDD (7,30). PRSs were calculated using 463,215 SNPs
shared between the discovery sample results and passing
quality control in all cohorts (missing rate ,2%, minor allele
frequency .0.01, and imputation INFO score .0.6). Thus,
PRSs were based on the same set of SNPs in all analyses to
increase comparability of results across cohorts. These
SNPs were clumped with PLINK (—clump-p1 1—clump-p2
1—clump-r2 0.25—clump-kb 500) and provided 73,576 lowly
correlated SNPs for MDD, 73,559 for SCZ, and 73,656 for BIP.
The MDD-PRS were based on five different thresholds of
GWAS significance for SNP inclusion (p , .01, .05, .1, .5,
and 1, respectively). The SCZ-PRS was based on a threshold
of p , .05, which provided optimal predictive power on SCZ
(4). The BIP-PRS was based on a threshold of p , .5 with best
predictive performance on BIP (46). The PRS were calculated
by summing the number of risk alleles weighted by their effect
size (score command in PLINK) (39).
Statistical Analyses
The prevalences at the population level of the five- and two-
domain dichotomous CT indicators were approximated from
this study assuming a population lifetime risk of MDD of 15%,140 Biological Psychiatry July 15, 2018; 84:138–147 www.sobp.org/jowith a lifetime risk of 20% in women and 10% in men (5,47).
The impact of the PRS, CT, and PRS 3 CT was first estimated
in the individual cohorts, and the effects in the total sample
were subsequently assessed with random-effect meta-
analysis. Within each cohort, the impact of CT on MDD was
assessed with logistic regression including sex as covariate.
The tests for the main effects of the PRS on MDD included sex
and the first three ancestry informative principal components
as covariates. Interaction analyses were conducted with the
5-domain continuous CT measure and with the 2-domain
dichotomous CT indicator. Interaction analyses of PRS 3 CT
were corrected for sex, three principal components, PRS, CT,
and the interaction terms of PRS and CT with sex and the
principal components in line with Keller’s recommendation
(48). With logistic regression, interaction is tested as departure
from multiplicativity (combined impact different from the
product of the individual effects), but it has been argued that
interaction as departure from additivity (combined impact
different from the sum of the individual effects) is more
meaningful biologically (49). For testing interaction as depar-
ture from additivity, the relative excess risks due to interaction






cbCT 11, and their 95% confidence
intervals (CIs) by means of bootstrapping with 10,000 itera-
tions. The impact of the PRS on MDD was further expressed as
variation explained on the liability scale, R2 (50). The PRS and
continuous five-domain CT measure were standardized (i.e.,
mean of 0 and variance of 1), and the presented odds ratios
(ORs) can thus be interpreted as increased MDD risk per
standard deviation increase in PRS or CT. The analyses were
conducted in R (51).
GRM-Based Analyses
The variance in MDD liability and CT explained by genotyped
SNPs (SNP heritability) was assessed with cross-product
Haseman-Elston regression (52). These analyses were cor-
rected for covariates by calculating the residuals of linear
regression of MDD and CT on sex, genotyping batch, and 20
ancestry-informative principal components. We included 20
principal components, because GRM-based analyses are
more sensitive to population stratification than PRS analyses
are (7). To test for interaction between CT and genome-wide
genetic effects in MDD, the genetic correlation between MDD
in unexposed individuals and MDD in exposed individuals can
give information about differences in genetic effects (53).
Unfortunately, the current data did not allow for the latter an-
alyses because of limited sample size (e.g., only 389 exposed
control subjects), while analyses had to be corrected for nine
cohorts.
RESULTS
Phenotypic Association Between MDD and CT
The five-domain continuous and dichotomous CT measures
were available for 1957 cases and 2002 control subjects, and
the two-domain dichotomous indicator was available for 3024
cases and 2741 control subjects. The prevalence of CT was
estimated at 0.25 based on the five-domain indicator (Table 1),
and at 0.17 for the two-domain indicator. As expected, theurnal
Table 1. Number of Depression Cases and Control Subjects and the 5-Domain CT Measure
Cohort
n




OR (p Value)Case Control Case Control Pop Case Control
Male and Female
COFAMS 56 22 0.70 0.23 0.30 7.22 (8.6 3 1024) 54.7 (21.4) 33.2 (11.6) 5.60 (1.2 3 1023)
NESDA 1143 272 0.53 0.21 0.26 4.18 (6.9 3 10219) 43.0 (14.6) 33.6 (9.1) 3.29 (3.4 3 10221)
RADIANT-UK 269 267 0.62 0.18 0.24 7.60 (1.1 3 10222) 46.4 (16.2) 32.7 (8.8) 4.08 (7.4 3 10221)
SHIP-0 340 993 0.36 0.23 0.25 1.94 (1.1 3 1026) 37.4 (12.3) 33.0 (8.4) 1.52 (7.4 3 10211)
SHIP-TREND 149 448 0.28 0.15 0.17 2.43 (1.5 3 1024) 36.9 (14.2) 31.6 (7.3) 1.72 (2.4 3 1027)
Total 1957 2002 0.50 0.21 0.25 3.80 (3.0 3 1026) 42.4 (15.1) 32.7 (8.4) 2.62 (1.4 3 1025)
Male Only
COFAMS 20 12 0.55 0.25 0.28 3.67 (1.1 3 1021) 50.2 (19.9) 34.8 (14.5) 2.94 (4.4 3 1022)
NESDA 357 111 0.53 0.19 0.22 4.70 (5.4 3 1029) 42.0 (13.5) 33.4 (9.1) 3.17 (3.4 3 1029)
RADIANT-UK 73 109 0.62 0.18 0.23 7.42 (7.8 3 1029) 45.5 (14.5) 33.2 (9.1) 3.43 (4.4 3 1028)
SHIP-0 112 562 0.39 0.25 0.26 1.95 (1.8 3 1023) 37.0 (9.1) 33.2 (7.8) 1.48 (1.8 3 1025)
SHIP-TREND 44 246 0.27 0.18 0.19 1.71 (1.5 3 1021) 35.7 (10.9) 32.3 (7.5) 1.42 (1.3 3 1022)
Total 606 1040 0.49 0.22 0.25 3.30 (8.7 3 1025) 41.3 (13.4) 33.0 (8.2) 2.18 (1.1 3 1024)
Female Only
COFAMS 36 10 0.78 0.20 0.32 14.0 (2.9 3 1023) 57.2 (22.0) 31.4 (7.0) 18.44 (2.2 3 1022)
NESDA 786 161 0.53 0.23 0.29 3.90 (2.1 3 10211) 43.5 (15.1) 33.7 (9.0) 3.30 (1.5 3 10213)
RADIANT-UK 196 158 0.61 0.17 0.26 7.70 (2.4 3 10215) 46.8 (16.8) 32.3 (8.6) 4.41 (3.0 3 10214)
SHIP-0 228 431 0.35 0.22 0.24 1.94 (1.7 3 1024) 37.5 (13.6) 32.6 (9.0) 1.57 (5.5 3 1027)
SHIP-TREND 105 202 0.29 0.11 0.15 3.10 (2.6 3 1024) 37.4 (15.4) 30.7 (6.9) 2.04 (1.2 3 1025)
Total 1351 962 0.50 0.19 0.25 4.03 (2.5 3 1026) 42.8 (15.8) 32.3 (8.6) 2.74 (3.6 3 1025)
Information is displayed for the cohorts that assessed childhood trauma (CT) with the Childhood Trauma Questionnaire covering the five domains
of sexual abuse, physical abuse, emotional abuse, physical neglect, and emotional neglect in a dichotomous five-domain indicator (exposed vs.
unexposed) and continuous measure (ranging from 25 to 125). For the dichotomous CT measure, the proportion of exposed individuals is
presented in cases, control subjects, and in terms of the full population (Pop) assuming a population prevalence of major depressive disorder of
15% with twice the prevalence in female subjects (20%) as in male subjects (10%), as well as the odds ratio (OR) of exposed versus unexposed
to develop major depressive disorder. For the continuous CT measure, the means are displayed in the original scale, and the OR for major
depressive disorder was assessed for the Childhood Trauma Questionnaire measure scaled to variance 1 and can thus be interpreted as
increased odds per SD increase in childhood trauma. The ORs were estimated with logistic regression including sex as covariate. The ORs in
the Total sample were estimated with random effect meta-analysis.
COFAMS, Cognition and Function in Mood Disorders Study; NESDA, Netherlands Study of Depression and Anxiety; SHIP, Study of Health in
Pomerania.
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Psychiatryprevalence was considerably larger in cases than control
subjects (0.50 vs. 0.21 for the five-domain measure and 0.35
vs. 0.14 for the two-domain measure). This was reflected in an
OR for MDD of 3.80 (p = 3.0 3 1026) for the five-domain
dichotomous measure, and an OR of 2.63 (p = 3.5 3 10218)
for the two-domain measure. For the five-domain continuous
CT measure, an OR for MDD of 2.62 (p = 1.4 3 1025) per
standard deviation increase in CT was found (Table 1,
Figure 1). The impact of CT on MDD was comparable in men
and women, with ORs of 2.18 (male subjects, p = 1.1 3 1024)
and 2.74 (female subjects, p = 3.6 3 1025) per standard de-
viation increase in the continuous five-domain CT measures
(Table 1). CT had an impact on MDD risk in all cohorts
(Table 1), and the five CTQ domains all had an impact on MDD
risk (Supplemental Table S4).PRS Analyses
The MDD-PRS based on all SNPs (inclusion threshold of p, 1)
had the greatest predictive power, with an OR of 1.34 (p =
5.1 3 10211, R2 = 1.71%) in the 1957 cases and 2002 controlBiologicalsubjects with availability of the five-domain CT measures
(Table 2). The SCZ-PRS and BIP-PRS also predicted MDD but
to a lesser extent than the MDD-PRS (Table 2), reflecting the
well-described genetic correlation among MDD, BIP, and SCZ
(7). Because gene-environment correlation can lead to
spurious G 3 E results (54), we tested for an association
between the MDD-PRS and CT. The MDD-PRS did predict the
five-domain continuous CT measure (b = .76, p = .004 in linear
regression), but this was approximated to reflect only a small
correlation in terms of the full population of w0.04
(Supplemental Table S5). No interaction between the PRS and
the five-domain continuous CTQ measure was found, with an
impact of MDD-PRS 3 CT on MDD with an OR of 1.05 (p = .52)
(Table 2). In addition, no evidence was found for interaction as
departure from additivity (relative excess risks due to interac-
tion = 0.83, 95% CI = 20.62 to 18.03). The BIP-PRS and SCZ-
PRS showed no evidence for interaction with the five-domain
CT measure.
Applying the two-domain dichotomous CT indicator of
sexual or physical abuse allowed inclusion of four additional
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Figure 1. Forest plot of impact on major
depressive disorder of the continuous childhood
trauma score covering the five domains of sexual
abuse, physical abuse, emotional abuse, emotional
neglect, and physical neglect. The odds ratio (OR)
represents one standard deviation increased in
childhood trauma. COFAMS, Cognition and Func-
tion in Mood Disorders Study; NESDA, Netherlands
Study of Depression and Anxiety; SHIP, Study of
Health in Pomerania.
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different instruments applied to assess CT). The total sample
size thus increased to 3024 cases and 2741 control subjects,
in which the MDD-PRS had an impact on MDD with an OR of
1.24 (p = 3.63 1025, R2 = 1.18%). The PRS did predict MDD in
DGN, but not in all QIMR cohorts, which is attributable to the
relatively small number of QIMR subjects with CT information
available compared with the full QIMR sample (in which PRS
predict MDD as expected). No interaction was found between
the PRS and two-domain dichotomous CT indicator (Table 3).
An alternative method sometimes applied to test for inter-
action as departure from additivity is linear regression with the
disease trait as outcome (28). We suggest caution in inter-
preting findings from this approach because this method has,
to the best of our knowledge, not been formally described.
Nevertheless, for reasons of completeness, this approach was
applied and also showed no evidence for interaction with the
five-domain CT measure (b = 2.004, p = .67) and the two-
domain CT measure (b = 2.005, p = .45).
GRM-Based Analyses
The SNP heritability of MDD was estimated at 0.14 (SE = 0.03;
p = 3.7 3 1028) based on the 6348 cases and 6751 control
subjects across the nine cohorts (Supplemental Table S1;
these analyses included additional individuals with no CT
information available). The SNP heritability of CT was esti-
mated at 0.00 (SE = 0.07; p , 1; n = 3959) for the five-domain
continuous measure, and at 0.09 (SE = 0.08; p = .27; n = 5765)
for the two-domain dichotomous indicator.
DISCUSSION
This study was conducted to test for interaction between
polygenic risk for MDD and CT in 5765 individuals from nine
cohorts contributing to the PGC that had a CT assessment
available. CT occurred in 25% of individuals based on an
indicator of five domains (sexual abuse, physical abuse,
emotional abuse, emotional neglect, and physical neglect) and
in 17% based on broad definition of two domains (sexual and/
or physical abuse). As expected, the prevalence was consid-
erably higher in cases than control subjects (0.50 vs. 0.21 for
the five-domain measure and 0.35 vs. 0.14 for the two-domain
measure). The five-domain measure was more detailed and
uniformly assessed in 1957 cases and 2002 control subjects;
the two-domain indicator was assessed heterogeneously142 Biological Psychiatry July 15, 2018; 84:138–147 www.sobp.org/joacross cohorts, but available for a larger sample comprising
3024 cases and 2741 control subjects. The PRSs explained
1.18% to 1.71% of variation in MDD risk. No evidence for
interaction between PRS and CT was found with the five-
domain CT measure (Table 2) and the two-domain CT indica-
tor (Table 3). Secondary analyses also showed no evidence for
interaction in analyses with PRS based on discovery results
from schizophrenia and bipolar disorder, in tests for interaction
as departure from additivity, in analyses in male and female
subjects separately (Supplemental Table S6), and in analysis in
the five separate domains of CT (Supplemental Table S7;
significance threshold 0.01 = 0.05/5). Analyses excluding
NESDA and RADIANT-UK showed no evidence for interaction
between the MDD-PRS (p value threshold 1) and five-domain
CT measure (OR = 1.06, p = .67) and two-domain CT mea-
sure (OR = 0.98, p = .61) in the remainder of the cohorts.
Remarkably, no interaction effects were found in NESDA
(OR = 1.08, 95% CI = 0.83–1.39, p = .56) and RADIANT-UK
(OR = 0.93, 95% CI = 0.66–1.31, p = .67) with the five-
domain CT measure (Table 2), which contrasts previous find-
ings in these respective cohorts by Peyrot et al. (27) (OR =
1.12, p = .018, discovery sample neffective = 15,295) and Mullins
et al. (28) (OR = 0.96 based on differently scaled PRS and CT,
p = .002, discovery sample neffective = 15,540). Aiming to clarify
these discrepancies, we analyzed PRS based on discovery
results from PGC MDD wave 2 with an effective sample size of
w37,000 (Supplemental Table S8) and confirmed the previ-
ously reported interaction effects in NESDA (OR = 1.38, 95%
CI = 1.07–1.76, p = .011) and RADIANT-UK (OR = 0.67, 95%
CI = 0.51–0.90, p = .006). Therefore, it appears that the ORs of
the interaction effects are reduced by adding deCODE (29),
Generation Scotland (41,42), GERA (43), iPsych (29), and UK
Biobank (44,45) to the PRS discovery sample. These dis-
crepancies in interaction results may reflect different study
designs in the discovery datasets with application of self-
reported depression status in UK Biobank and clinical re-
cords in iPsych and GERA, contrasting the semistructured
interviews (such as the Structured Clinical Interview for DSM,
Composite International Diagnostic Interview, and Mini Inter-
national Neuropsychiatric Interview) applied in most PGC
cohorts (29). However, these discrepancies may also reflect
random variation in effects with discovery sample size
increasing from w37,000 to w110,000. The latter possibility
seems more likely since 1) we observe an increase in the
variance explained by the PRS from 0.66% (p = 2.8 3 1025) tournal
Table 2. Impact on MDD of PRS and Their Interaction With the Five-Domain CT Continuous Measure of Sexual Abuse,




PRS PRS 3 CT
Case Control OR (95% CI) p Value R2 (SE, %) OR (95% CI) p Value RERI (95% CI)
COFAMS
MDD p , 1 56 22 1.41 (0.82:2.49) .212 3.13 (4.61) 0.38 (0.08:1.74) .201 22.07 (NA:NA)
SCZ p , .05 56 22 1.18 (0.59:2.33) .623 0.54 (1.95) 0.01 (0.00:0.37) .030 262.80 (NA:NA)
BIP p , .5 56 22 0.85 (0.44:1.58) .612 0.44 (1.77) 0.13 (0.01:0.96) .076 22.46 (NA:NA)
NESDA
MDD p , 1 1143 272 1.24 (1.08:1.42) .002 1.33 (0.84) 1.08 (0.83:1.39) .556 1.06 (21.07:10.48)
SCZ p , .05 1143 272 1.25 (1.07:1.46) .006 1.02 (0.74) 0.91 (0.68:1.22) .510 0.39 (–1.18:8.78)
BIP p , .5 1143 272 1.14 (1.00:1.31) .049 0.53 (0.53) 1.19 (0.92:1.52) .182 1.97 (–0.28:17.61)
RADIANT-UK
MDD p , 1 269 267 1.64 (1.35:2.00) 6.8 3 1027 5.90 (2.19) 0.93 (0.66:1.31) .670 4.42 (21.78:178.22)
SCZ p , .05 269 267 1.61 (1.31:2.01) 1.3 3 1025 4.44 (1.92) 0.90 (0.62:1.30) .581 9.87 (20.43:275.79)
BIP p , .5 269 267 1.19 (1.00:1.43) .053 0.85 (0.86) 1.02 (0.75:1.38) .920 4.25 (20.95:137.22)
SHIP-0
MDD p , 1 340 993 1.30 (1.14:1.48) 1.0 3 1024 1.81 (0.91) 1.02 (0.89:1.18) .737 0.52 (20.18:2.86)
SCZ p , .05 340 993 1.05 (0.91:1.22) .470 0.06 (0.17) 0.95 (0.83:1.10) .497 20.22 (20.97:0.60)
BIP p , .5 340 993 0.95 (0.84:1.09) .477 0.06 (0.16) 0.92 (0.81:1.05) .230 20.12 (20.89:0.96)
SHIP-TREND
MDD p , 1 149 448 1.33 (1.09:1.63) .005 2.10 (1.47) 1.28 (0.96:1.72) .103 0.22 (20.50:1.43)
SCZ p , .05 149 448 1.10 (0.89:1.37) .379 0.20 (0.46) 0.90 (0.71:1.15) .404 20.09 (21.09:1.62)
BIP p , .5 149 448 1.20 (0.99:1.46) .071 0.86 (0.95) 1.05 (0.85:1.32) .659 0.07 (20.75:1.51)
Total
MDD p , .01 1957 2002 1.22 (1.08:1.37) .001 0.58 (0.26) 1.02 (0.89:1.17) .790 20.17 (22.86:10.25)
MDD p , .05 1957 2002 1.29 (1.14:1.45) 4.0 3 1025 1.08 (0.36) 0.98 (0.79:1.22) .846 0.27 (22.46:15.37)
MDD p , .1 1957 2002 1.34 (1.18:1.53) 1.0 3 1025 1.49 (0.42) 1.01 (0.84:1.22) .910 0.51 (22.02:15.72)
MDD p , .5 1957 2002 1.35 (1.22:1.48) 2.2 3 1029 1.70 (0.45) 1.03 (0.86:1.23) .755 0.84 (20.52:22.18)
MDD p , 1 1957 2002 1.34 (1.23:1.47) 5.1 3 10211 1.71 (0.45) 1.05 (0.91:1.20) .519 0.83 (20.62:18.03)
SCZ p , .05 1957 2002 1.22 (1.04:1.43) .013 0.57 (0.26) 0.91 (0.79:1.04) .172 20.15 (22.87:11.06)
BIP p , .5 1957 2002 1.10 (0.98:1.23) .114 0.16 (0.14) 1.00 (0.85:1.18) .997 0.39 (21.13:20.78)
The impact on major depressive disorder (MDD) is displayed for polygenic risk scores (PRSs) and their interaction with the five-domain
continuous childhood trauma (CT) measure including sexual abuse, physical abuse, emotional abuse, physical neglect, and emotional neglect.
The impact of the PRS is presented as the odds ratio (OR) from logistic regression corrected for sex and three principal components, as well as
with the variance explained by the PRS on the liability scale. Interaction of PRS with CT (PRS 3 CT) was assessed as departure from
multiplicativity with logistic regression while additionally correcting for the main effects of PRS and CT. Interaction as departure from additivity
was expressed as the relative excess risks due to interaction (RERI) estimated as described in the main text, and their 95% confidence intervals
(CIs) were estimated with bootstrapping with 10,000 iterations. The PRSs were based on discovery genome-wide association results from MDD,
schizophrenia (SCZ), and bipolar disorder (BIP). Results in the Total sample were based on random-effect meta-analysis of the effects in the
individual cohorts.
COFAMS, Cognition and Function in Mood Disorders Study; NA, not available; NESDA, Netherlands Study of Depression and Anxiety; SHIP,
Study of Health in Pomerania.
Childhood Trauma and Polygenic Risk for Depression
Biological
Psychiatry1.71% (p = 5.1 3 10211) (Supplemental Table S8), which cor-
responds with the increase predicted from theory given the
increased sample size (55); 2) a genetic correlation of 0.91 to
0.96 between the PGC wave 2 discovery results and the
extended discovery results as estimated with LD-score
regression (30); and 3) an overlap of the 95% CI of the inter-
action effects based on the PGC discovery sample and the
larger discovery sample applied in this article (Supplemental
Table S8). In other words, our results suggest that the addi-
tional discovery cohorts (deCODE, Generation Scotland,
GERA, iPsych, and UK Biobank) capture the same genetic
information that the PGC cohorts do. Therefore, we hypothe-
size that the previously reported interaction results in NESDABiological(27) and RADIANT-UK (28) were both chance findings. The fact
that these findings were both significant in an opposite direc-
tion may reflect the statistical vulnerability of interaction testing
(48,54,56).
A source of spurious interaction effects can be found in
GE correlation as explained for twin analyses by Purcell (54).
Notably, the PRS based on the PGC wave 2 discovery
results were slightly more correlated with CT in the full
population (with w20.09 in NESDA and 0.13 in RADIANT-
UK) than the PRS based on the extended sample was
(w0.02 and w0.06, respectively). A simulation study sug-
gested that the type I error rate can indeed be inflated in the
context of GE correlation, but to a modest extent of 0.075Psychiatry July 15, 2018; 84:138–147 www.sobp.org/journal 143
Table 3. Proportion Exposed to CT Measured as Either Sexual or Physical Abuse, and Its Interaction With PRSs (With SNP






CT PRS PRS 3 CT
Case Control Case Control Pop OR p Value OR (95% CI) p Value R2 (SE, %) OR (95% CI)
p
Value
COFAMS 56 22 0.43 0.27 0.30 1.85 .268 1.41 (0.82:2.49) .212 3.13 (4.61) 0.51 (0.21:1.05) .088
DGN 461 458 0.40 0.20 0.22 2.49 1.9 3 1029 1.30 (1.13:1.50) 2.5 3 1024 1.77 (0.94) 1.06 (0.91:1.22) .465
NESDA 1133 271 0.32 0.11 0.14 3.83 8.3 3 10211 1.24 (1.09:1.43) .002 1.36 (0.85) 1.06 (0.87:1.28) .587
QIMR_3 186 55 0.44 0.18 0.22 3.66 7.0 3 1024 1.07 (0.79:1.46) .670 0.13 (0.60) 0.82 (0.52:1.25) .355
QIMR_3_M7 126 29 0.48 0.31 0.34 2.10 .092 1.16 (0.75:1.80) .494 0.66 (1.80) 0.83 (0.49:1.40) .496
QIMR_6 121 107 0.38 0.23 0.29 2.05 .016 0.90 (0.67:1.19) .452 0.30 (0.78) 0.87 (0.61:1.22) .418
QIMR_C 180 46 0.40 0.33 0.33 1.36 .387 0.83 (0.58:1.17) .297 0.92 (1.70) 0.89 (0.60:1.30) .564
RADIANT-UK 262 263 0.42 0.15 0.19 4.33 1.5 3 10211 1.61 (1.33:1.97) 2.1 3 1026 5.46 (2.14) 1.04 (0.83:1.30) .761
SHIP_0 352 1042 0.22 0.12 0.14 2.10 6.0 3 1026 1.31 (1.15:1.49) 4.2 3 1025 1.95 (0.93) 0.97 (0.86:1.10) .606
SHIP-TREND 147 448 0.20 0.08 0.10 2.77 2.0 3 1024 1.34 (1.09:1.64) .005 2.14 (1.50) 1.08 (0.88:1.35) .460
Total 3024 2741 0.35 0.14 0.17 2.63 3.5 3 10218 1.24 (1.12:1.37) 3.6 3 1025 1.18 (0.31) 1.00 (0.93:1.07) .894
The impact on major depressive disorder (MDD) is displayed for polygenic risk scores (PRSs) and their interaction with the childhood trauma (CT)
dichotomous indicator covering sexual abuse and physical abuse. The prevalence of CT is presented in MDD cases, control subjects, and in terms
of the full population (Pop), assuming a population prevalence of MDD of 15% with twice the prevalence in female subjects (20%) as in male
subjects (10%). The impact of the PRS and CT is presented as the odds ratio (OR) from logistic regression corrected for sex and three principal
components, as well as with the variance explained by the PRS on the liability scale. Interaction of PRS with CT (PRS 3 CT) was assessed as
departure from multiplicativity with logistic regression while additionally correcting for the main effects of PRS and CT. The PRSs were based on
discovery genome-wide association results from MDD including all single nucleotide polymorphisms (SNPs), that is, with significance threshold
p , 1.
COFAMS, Cognition and Function in Mood Disorders Study; DGN, Depression Gene Network; NESDA, Netherlands Study of Depression and
Anxiety; QIMR, Queensland Institute of Medical Research (subdivided in four batches: _3, _3_M7, _6, and _C); SHIP, Study of Health in Pomerania.
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and E (Supplemental Methods). It is therefore unlikely that
the G 3 E interactions previously found would be attribut-
able to GE correlation.
The current study has both strengths and limitations. First,
this study is the largest to date to test for interaction between
PRSs and CT in MDD risk. Second, PRSs were based on a
powerful discovery GWAS with w110,000 individuals. Third,
diagnoses were DSM based, aiming to select clinically relevant
cases of MDD. A limitation of our study is that CT was not
assessed uniformly across cohorts for the two-domain mea-
sure, but analyses restricted to cohorts assessed uniformly
with the five-domain CTQ instrument showed similar results.
Although this study is the largest to date, power to detect an
interaction effect between PRS and CT was still limited (power
$ 0.8 for interaction effects with OR # 0.83 or OR $ 1.21 for
analyses with the two-domain CT measure in 5765 individuals,
based on power analyses with QUANTO software) (57). Of
note, tests of interaction with PRS do not rule out interaction
with individual SNPs; the PRSs were based on many SNPs,
some but not all of which may be involved in interaction. The
current study tested for interaction with CT because CT has
been hypothesized to define a distinct type of MDD (26), but
other environmental factors could have also been tested.
Nevertheless, testing too many environmental conditions
assessed with a variety of instruments may increase risk of
publication bias when significant findings would be published
selectively (16,58).
Lastly, we would like to emphasize the complex nature of
interaction testing with PRS based on genome-wide SNPs. For
analyses with twin data, Purcell (54) described the distinction144 Biological Psychiatry July 15, 2018; 84:138–147 www.sobp.org/jobetween qualitative interaction (different genes have an effect
across different environments) and quantitative interactions
(the same genes have an effect but they explain a different
proportion of variance). In an attempt to elucidate some of the
characteristics of interaction testing with PRS, we conducted a
second simulation study constructing PRS from simulated
SNP-level data for different underlying genetic architectures
(Supplemental Methods and Supplemental Table S9). First, we
note that the discovery results are typically based on a dis-
covery sample with an unknown mixture of individuals unex-
posed (CT = 0) and individuals exposed to CT (CT = 1). When
assuming qualitative genome-wide interaction with different
directions of SNP effects in exposed and unexposed
individuals (explaining the same proportion of variance in both
groups), the discovery GWAS would mainly tag the effects in
unexposed individuals that form the majority of the discovery
sample. Consequently, negative interaction between PRS and
CT would be detected under this scenario. Second and con-
trary, for quantitative interaction, a positive interaction effect
may be expected when SNPs would explain more variance in
exposed individuals.
To conclude, no overall evidence was found for interaction
between PRS and CT. Previously found interaction effects
(27,28) were no longer significant when applying more
powerful discovery results. This study provides a cautionary
tale for interaction analyses with PRS: it emphasizes the need
to perform meta-analyses on results across different cohorts
to obtain external validity. The quest continues to clarify the
nature of the heterogeneity of MDD, but the present study has
shown that the heterogeneity is unlikely to be attributable to
moderation of genome-wide genetic effects by CT. Futureurnal
Childhood Trauma and Polygenic Risk for Depression
Biological
Psychiatryresearch may focus on interaction effects between CT and
individual SNPs. We hereby call for large GWAS cohorts to
assess CT in a uniform manner to facilitate such research in
the years to come.
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